CMOs in global supply chains boost quality risks; Weird drug names;

> Drugmakers are seeing firsthand that extended supply chains--especially those that include third-party manufacturers throughout the world--exponentially increases the risk of quality issues. Article 

> There's a reason so many drug names look so weird. Story

> GlaxoSmithKline has agreed to publish the prices it charges UNICEF for children's vaccines. Story

> Dalton Pharma Services in Canada will provide aseptic fill/finish services and analytical support for Zafgen's lead obesity treatment. Dalton's release

> McLaren Software and CaudexVitalis have teamed on document management and control applications for the pharma and healthcare sectors in Central Europe. McLaren announcement

> Alexion Pharmaceuticals of Cheshire, CT, is adding lab and office space as well as jobs in Smithfield, RI. Story

> Bulk drug maker Unimark Remedies says it's using biocatalysis technology in trial production runs of HIV-fighter Atazanavir for 25 to 30 percent production cost savings. Story

> Authentix is taking the wraps off the Comprehensive Authentication Traceability System (CATS), which the company claims will provide product oversight from raw materials to finished product at the point of sale. Authentix release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.